BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 21156980)

  • 1. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
    Mathew B; Lennon FE; Siegler J; Mirzapoiazova T; Mambetsariev N; Sammani S; Gerhold LM; LaRiviere PJ; Chen CT; Garcia JG; Salgia R; Moss J; Singleton PA
    Anesth Analg; 2011 Mar; 112(3):558-67. PubMed ID: 21156980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
    Lennon FE; Mirzapoiazova T; Mambetsariev B; Salgia R; Moss J; Singleton PA
    Anesthesiology; 2012 Apr; 116(4):857-67. PubMed ID: 22343475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
    Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
    J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
    Lennon FE; Mirzapoiazova T; Mambetsariev B; Poroyko VA; Salgia R; Moss J; Singleton PA
    PLoS One; 2014; 9(3):e91577. PubMed ID: 24662916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased μ-opioid receptor expression in metastatic lung cancer.
    Singleton PA; Mirzapoiazova T; Hasina R; Salgia R; Moss J
    Br J Anaesth; 2014 Jul; 113 Suppl 1(Suppl 1):i103-8. PubMed ID: 24920011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
    Fujioka N; Nguyen J; Chen C; Li Y; Pasrija T; Niehans G; Johnson KN; Gupta V; Kratzke RA; Gupta K
    Anesth Analg; 2011 Dec; 113(6):1353-64. PubMed ID: 22003224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells.
    Stoyanov E; Uddin M; Mankuta D; Dubinett SM; Levi-Schaffer F
    Lung Cancer; 2012 Jan; 75(1):38-44. PubMed ID: 21733595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. micro-Opioid receptor activation prevents acute hepatic inflammation and cell death.
    Chakass D; Philippe D; Erdual E; Dharancy S; Malapel M; Dubuquoy C; Thuru X; Gay J; Gaveriaux-Ruff C; Dubus P; Mathurin P; Kieffer BL; Desreumaux P; Chamaillard M
    Gut; 2007 Jul; 56(7):974-81. PubMed ID: 17299060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mu-opioid receptor modulation of calcium channel current in periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR-1.
    Connor M; Schuller A; Pintar JE; Christie MJ
    Br J Pharmacol; 1999 Apr; 126(7):1553-8. PubMed ID: 10323586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 11. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma.
    Gorur A; Patiño M; Takahashi H; Corrales G; Pickering CR; Gleber-Netto FO; Myers JN; Cata JP
    Life Sci; 2021 Aug; 278():119541. PubMed ID: 33930368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain.
    Páldy E; Bereczki E; Sántha M; Wenger T; Borsodi A; Zimmer A; Benyhe S
    Neurochem Int; 2008 Dec; 53(6-8):309-16. PubMed ID: 18804501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation.
    Philippe D; Dubuquoy L; Groux H; Brun V; Chuoï-Mariot MT; Gaveriaux-Ruff C; Colombel JF; Kieffer BL; Desreumaux P
    J Clin Invest; 2003 May; 111(9):1329-38. PubMed ID: 12727924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mu-opioid receptor and delta-opioid receptor differentially regulate microglial inflammatory response to control proopiomelanocortin neuronal apoptosis in the hypothalamus: effects of neonatal alcohol.
    Shrivastava P; Cabrera MA; Chastain LG; Boyadjieva NI; Jabbar S; Franklin T; Sarkar DK
    J Neuroinflammation; 2017 Apr; 14(1):83. PubMed ID: 28407740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.
    Clayton CC; Bruchas MR; Lee ML; Chavkin C
    Mol Pharmacol; 2010 Mar; 77(3):339-47. PubMed ID: 19959593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
    Melkes B; Hejnova L; Novotny J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of perioperative opioids on cancer recurrence: a hypothesis.
    Singleton PA; Moss J
    Future Oncol; 2010 Aug; 6(8):1237-42. PubMed ID: 20799870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
    Cinar R; Szücs M
    J Pharmacol Exp Ther; 2009 Aug; 330(2):567-74. PubMed ID: 19448142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche.
    Castañón E; Soltermann A; López I; Román M; Ecay M; Collantes M; Redrado M; Baraibar I; López-Picazo JM; Rolfo C; Vidal-Vanaclocha F; Raez L; Weder W; Calvo A; Gil-Bazo I
    Cancer Lett; 2017 Aug; 402():43-51. PubMed ID: 28549790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
    Singleton PA; Moreno-Vinasco L; Sammani S; Wanderling SL; Moss J; Garcia JG
    Am J Respir Cell Mol Biol; 2007 Aug; 37(2):222-31. PubMed ID: 17395891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.